Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/S2213-2600(21)00103-X http://scihub22266oqcxt.onion/10.1016/S2213-2600(21)00103-X 33872590!8051931!33872590     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lancet+Respir+Med 2021 ; 9 (6): 643-654 Nephropedia Template TP {{tp|p=33872590|t=2021. Interleukin-6: obstacles to targeting a complex cytokine in critical illness |pdf=|usr=}}{{33872590}} gab.com Text Interleukin-6: obstacles to targeting a complex cytokine in critical illness JO: Lancet Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=33872590 #FOAvip Circulating concentrations of the pleiotropic cytokine interleukin-6 (IL-6) are known to be increased in pro-inflammatory critical care syndromes, such as sepsis and acute respiratory distress syndrome. Elevations in serum IL-6 concentrations in patients with severe COVID-19 have led to renewed interest in the cytokine as a therapeutic target. However, although the pro-inflammatory properties of IL-6 are widely known, the cytokine also has a series of important physiological and anti-inflammatory functions. An adequate understanding of the complex processes by which IL-6 signalling occurs is crucial for the correct interpretation of IL-6 concentrations in the blood or lung, the use of IL-6 as a critical care biomarker, or the design of effective anti-IL-6 strategies. Here, we outline the role of IL-6 in health and disease, explain the different types of IL-6 signalling and their contribution to the net biological effect of the cytokine, describe the approaches to IL-6 inhibition that are currently available, and discuss implications for the future use of treatments such as tocilizumab in the critical care setting. Twit Text FOAVip Interleukin-6: obstacles to targeting a complex cytokine in critical illness ????Lancet Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=33872590 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33872590 #FOAvip English Wikipedia <ref>{{Cite pmid|33872590}}</ref> Interleukin-6: obstacles to targeting a complex cytokine in critical illness #MMPMID33872590 McElvaney OJ; Curley GF; Rose-John S; McElvaney NG Lancet Respir Med 2021[Jun]; 9 (6): 643-654 PMID33872590show ga Circulating concentrations of the pleiotropic cytokine interleukin-6 (IL-6) are known to be increased in pro-inflammatory critical care syndromes, such as sepsis and acute respiratory distress syndrome. Elevations in serum IL-6 concentrations in patients with severe COVID-19 have led to renewed interest in the cytokine as a therapeutic target. However, although the pro-inflammatory properties of IL-6 are widely known, the cytokine also has a series of important physiological and anti-inflammatory functions. An adequate understanding of the complex processes by which IL-6 signalling occurs is crucial for the correct interpretation of IL-6 concentrations in the blood or lung, the use of IL-6 as a critical care biomarker, or the design of effective anti-IL-6 strategies. Here, we outline the role of IL-6 in health and disease, explain the different types of IL-6 signalling and their contribution to the net biological effect of the cytokine, describe the approaches to IL-6 inhibition that are currently available, and discuss implications for the future use of treatments such as tocilizumab in the critical care setting. |*Antibodies, Monoclonal, Humanized/immunology/pharmacology[MESH] |*COVID-19/immunology/physiopathology/therapy[MESH] |*Interleukin-6/antagonists & inhibitors/blood/immunology[MESH] |Biomarkers/blood[MESH] |Critical Illness[MESH] |Humans[MESH] |Immunologic Factors/immunology/pharmacology[MESH]Interleukin-6: obstacles to targeting a complex cytokine in critical i(epmc).pdf DeepDyve Pubget Overpricing